[1]
Kyung-ann Lee et al. 2023. Comparison of the efficacy and safety of oligomeric proanthocyanidins and nifedipine in patients with primary Raynaud’s phenomenon: An open-label, randomized, prospective pilot study. Archives of Rheumatology. 38, 3 (Sep. 2023), 477–479. DOI:https://doi.org/10.46497/ArchRheumatol.2023.9212.